Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy.

Briere D, Sudhakar N, Woods DM, Hallin J, Engstrom LD, Aranda R, Chiang H, Sodré AL, Olson P, Weber JS, Christensen JG.

Cancer Immunol Immunother. 2018 Mar;67(3):381-392. doi: 10.1007/s00262-017-2091-y. Epub 2017 Nov 9.

PMID:
29124315
2.

Predictors of responses to immune checkpoint blockade in advanced melanoma.

Jacquelot N, Roberti MP, Enot DP, Rusakiewicz S, Ternès N, Jegou S, Woods DM, Sodré AL, Hansen M, Meirow Y, Sade-Feldman M, Burra A, Kwek SS, Flament C, Messaoudene M, Duong CPM, Chen L, Kwon BS, Anderson AC, Kuchroo VK, Weide B, Aubin F, Borg C, Dalle S, Beatrix O, Ayyoub M, Balme B, Tomasic G, Di Giacomo AM, Maio M, Schadendorf D, Melero I, Dréno B, Khammari A, Dummer R, Levesque M, Koguchi Y, Fong L, Lotem M, Baniyash M, Schmidt H, Svane IM, Kroemer G, Marabelle A, Michiels S, Cavalcanti A, Smyth MJ, Weber JS, Eggermont AM, Zitvogel L.

Nat Commun. 2017 Sep 19;8(1):592. doi: 10.1038/s41467-017-00608-2.

3.

Essential role for histone deacetylase 11 (HDAC11) in neutrophil biology.

Sahakian E, Chen J, Powers JJ, Chen X, Maharaj K, Deng SL, Achille AN, Lienlaf M, Wang HW, Cheng F, Sodré AL, Distler A, Xing L, Perez-Villarroel P, Wei S, Villagra A, Seto E, Sotomayor EM, Horna P, Pinilla-Ibarz J.

J Leukoc Biol. 2017 Aug;102(2):475-486. doi: 10.1189/jlb.1A0415-176RRR. Epub 2017 May 26.

PMID:
28550123
4.

T cells lacking HDAC11 have increased effector functions and mediate enhanced alloreactivity in a murine model.

Woods DM, Woan KV, Cheng F, Sodré AL, Wang D, Wu Y, Wang Z, Chen J, Powers J, Pinilla-Ibarz J, Yu Y, Zhang Y, Wu X, Zheng X, Weber J, Hancock WW, Seto E, Villagra A, Yu XZ, Sotomayor EM.

Blood. 2017 Jul 13;130(2):146-155. doi: 10.1182/blood-2016-08-731505. Epub 2017 May 26.

5.

HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade.

Woods DM, Sodré AL, Villagra A, Sarnaik A, Sotomayor EM, Weber J.

Cancer Immunol Res. 2015 Dec;3(12):1375-85. doi: 10.1158/2326-6066.CIR-15-0077-T. Epub 2015 Aug 21.

6.

Histone deacetylase 11: A novel epigenetic regulator of myeloid derived suppressor cell expansion and function.

Sahakian E, Powers JJ, Chen J, Deng SL, Cheng F, Distler A, Woods DM, Rock-Klotz J, Sodre AL, Youn JI, Woan KV, Villagra A, Gabrilovich D, Sotomayor EM, Pinilla-Ibarz J.

Mol Immunol. 2015 Feb;63(2):579-85. doi: 10.1016/j.molimm.2014.08.002. Epub 2014 Aug 23.

7.

An efficient low cost method for gene transfer to T lymphocytes.

Chicaybam L, Sodre AL, Curzio BA, Bonamino MH.

PLoS One. 2013;8(3):e60298. doi: 10.1371/journal.pone.0060298. Epub 2013 Mar 26.

8.

Chimeric antigen receptors in cancer immuno-gene therapy: current status and future directions.

Chicaybam L, Sodré AL, Bonamino M.

Int Rev Immunol. 2011 Oct-Dec;30(5-6):294-311. doi: 10.3109/08830185.2011.595855. Review.

PMID:
22053970

Supplemental Content

Loading ...
Support Center